Dr. Tripathy on Breast Cancer with Bone Metastases

Debu Tripathy, MD
Published: Saturday, Jul 16, 2011

Debu Tripathy, MD, professor of medicine and co-leader of the Women's Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, discusses the options available for breast cancer patients with bone metastases at the 28th Annual Miami Breast Cancer Conference.

Tripathy explains that bisphosphonates have been approved to lower skeletal-related events (SREs). These agents are becoming more commonly used. An exciting new agent is denosumab (Xgeva); Tripathy explains that this drug has shown more benefits and advantages, compared to other approved drugs, for the treatment of SREs.
Debu Tripathy, MD, professor of medicine and co-leader of the Women's Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, discusses the options available for breast cancer patients with bone metastases at the 28th Annual Miami Breast Cancer Conference.

Tripathy explains that bisphosphonates have been approved to lower skeletal-related events (SREs). These agents are becoming more commonly used. An exciting new agent is denosumab (Xgeva); Tripathy explains that this drug has shown more benefits and advantages, compared to other approved drugs, for the treatment of SREs.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x